Bioventus Inc. (BVS)

4,0250 +0,0550 (+1,38%) A partir del 09:48AM EDT. Mercado abierto.

Bioventus Inc.

4721 Emperor Boulevard
Suite 100
Durham, NC 27703
United States
919 474 6700
https://www.bioventus.com

Sector(es): Healthcare
Sector: Medical Devices
Empleados a tiempo completo: 970

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Mark L. Singleton	Senior VP & CFO	740,04k	N/A	1970
Mr. Anthony D'Adamio	Senior VP, General Counsel & Corporate Secretary	705,38k	N/A	1961
Mr. Robert E. Claypoole	President, CEO & Director	N/A	N/A	1972
Mr. Mike Crowe B.S., M.B.A.	Senior Vice President of Operations	N/A	N/A	N/A
Mr. David Crawford	Vice President of Investor Relations & Treasurer	N/A	N/A	N/A
Ms. Katrina J. Church J.D.	Senior VP & Chief Compliance Officer	N/A	N/A	1962
Ms. Helen Leupold	Senior VP & Chief Human Resources Officer	N/A	N/A	N/A
Mr. Larry Chen	Managing Director of China & Asia Pacific	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Gobierno corporativo

El ISS Governance QualityScore de Bioventus Inc., a día 1 de mayo de 2024, es 8. Las puntuaciones base son Auditoría: 10; Tablero: 6; Derechos de los accionistas: 6; Compensación: 9.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.